NewsRoom Articles - BioMedWire (BMW)

TuesdayApr 22, 2025 10:00 am

UnitedHealth Records Lower Revenue as Medical Advantage Use Grows

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast for 2025 after its customers on Medicare Advantage made use of their policies a lot more than the company had anticipated. The first quarter of the year registered a lower financial performance than the company had expected. The stocks of the firm tumbled after this news on Thursday and the report released shook insurance stocks across the board. UnitedHealth said that MA plans saw more activity than the company had projected for the year. This was particularly evident in outpatient services and doctor visits, all…

TuesdayApr 22, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M U.S. sales opportunity as first abuse-deterrent opioid patch Strategic sports partnership with Charlotte FC boosts brand visibility and community presence Strengthening IP for Long-Term Market Protection Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number…

MondayApr 21, 2025 1:00 pm

Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat

An increase in deaths from COVID-19 underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments. Soligenix is addressing this need through the development of CiVax, its proprietary, heat-stable COVID-19 subunit vaccine candidate. Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants. Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases…

MondayApr 21, 2025 10:00 am

Study Finds Link Between Childhood Maltreatment and Elevated Risk of Psoriasis, Rheumatoid Arthritis

A new study whose findings appeared in the journal Heliyon has found that individuals that suffered neglect, abuse and other forms of maltreatment during their childhood had a notably elevated risk of being diagnosed with chronic immune-related disorders later on in their lives. Psoriasis and rheumatoid arthritis were particularly noted in the study subjects and women exhibited a higher likelihood of developing these immune disorders. The researchers were interested in investigating whether exposure to abuse early in life had a connection with inflammatory disorders that are immune system mediated, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel conditions, and psoriasis.…

ThursdayApr 17, 2025 10:00 am

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights. The report indicates that this market is entering a new phase of growth propelled by the increasing prevalence of malignant brain tumors, such as glioblastoma, in addition to a remarkable increase in investments in the neuro-oncology field. Many cutting-edge interventions are being integrated in the way patients are treated. These include tumor-treating fields and…

TuesdayApr 15, 2025 10:00 am

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential to detect Parkinson’s disease years before the disease’s symptoms start manifesting. The study’s findings appeared in the Nature Aging journal. Approximately 153,000 individuals live with Parkinson’s disease in the United Kingdom, and the team that conducted this recent research is optimistic that their innovation could revolutionize how early the disease can be detected. This early diagnosis would then allow treatment teams to initiate interventions that improve the clinical outcomes for patients. The new test developed focuses on analyzing fragments of transfer RNA (tRFs), which are…

TuesdayApr 15, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients. AVERSA technology can be incorporated into any transdermal patch. The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch. In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support…

MondayApr 14, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of patients Nutriband recently announced two significant partnerships poised to expand its manufacturing capabilities and market reach These partnerships, along with the company’s already existing alliances, align with Nutriband's core mission of developing transdermal pharmaceutical products Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on…

FridayApr 11, 2025 10:45 am

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to quality care, in profitable shift from fee-for-service to value-based models. Its system helps decipher complex insurance contracts to maximize reimbursements. The software helps decipher complex insurance contracts to maximize reimbursements, integrating smoothly with major electronic health record systems to identify high-risk patients and care gaps. Adageis is continuously working with investors to expand its offerings for a growing list of small and independent practices. Adageis, a forward-thinking healthcare technology company focused on value-based care solutions, is helping clinics and medical groups measure how their delivery…

FridayApr 11, 2025 10:00 am

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that blocking the HPGDS enzyme can be a viable way to improve patients’ response to immunotherapy since the activity of this enzyme contributes to immunotherapy resistance. This approach can also increase immunotherapy response in other types of cancer with similar attributes to those of melanoma. Over the last 10 years, significant advances have been made in leveraging immunotherapy to treat melanoma and other cancers. However, more than half (65%) of melanoma patients don’t respond to immunotherapy. TAMs (tumor-associated macrophages) play a major role in this immunotherapy…